同种异体骨髓单个核细胞移植治疗大鼠急性心肌梗死实验研究

目的探讨大鼠同种异体骨髓单个核细胞（bone marrow mononuclear cells，BM—MNCs）在急性心肌梗死区分化增殖潜能及其修复重建心肌作用。方法健康雄性Wistar大鼠24只，用结扎冠状动脉左前降支的方法建立大鼠心肌梗死模型，随机分为对照组（AMI＋培养基，12只），移植组（AMI＋BM—MNCs，12只）；分别将制备的培养基和BM—MNCs悬液心外膜下植入梗死心肌周围。移植术后4周，观察心肌梗死区及其周边区组织形态学特点、心肌梗死面积变化。结果实验组与对照组相比心肌梗死面积明显缩小（P〈0．01）；实验组心肌梗死区内有BrdU标记阳性的BM—MNCs移植细胞存活，向心肌源性细胞分化并且诱导了大量的新生毛细血管。结论同种异体BM—MNCs移植在细胞水平完成了对心肌梗死区再心肌化和再血管化过程，可以改善急性心肌梗死后的心脏功能。     

人脐血单个核细胞移植治疗急性一氧化碳中毒后迟发脑病1年随访

背景：研究报道在特定的体内外环境下,脐血间充质干细胞能够诱导分化成为包括神经干细胞在内的多种组织细胞。 目的：评价人脐血单个核细胞经腰穿途径移植后治疗急性一氧化碳中毒后迟发性脑病的疗效及安全性。 方法：一氧化碳中毒后迟发性脑病患者60例随机分为2组。对照组给予高压氧及药物治疗;治疗组采用鞘内注射法将经密度梯度离心法分离出的人脐血单个核细胞移植到一氧化碳中毒性脑病患者的蛛网膜下腔,余治疗方法同对照组。分别于人脐血单个核细胞移植前、移植后3,9,12个月对患者进行简易精神状态检查法、改良Asworth肌肉痉挛程度分级及日常生活量表评分检查;比较两组患者MRI变化;同时对随诊患者行胸片、心电图及血生化检查,客观评价人脐血单个核细胞移植的安全性。 结果与结论：人脐血单个核细胞移植3,9,12个月,治疗组Asworth肌肉痉挛程度分级评分均显著低于对照组(P=0.032);移植后9,12个月简易智力状况检查法及日常生活量表评分均显著高于对照组(P < 0.05);两组患者神经功能在各时间点的变化趋势相似。人脐血单个核细胞移植后12个月MRI检查结果显示,治疗组患者MRI改善程度较对照组明显。提示鞘内注射移植人脐血单个核细胞治疗一氧化碳中毒后迟发脑病疗效优于高压氧治疗。中国组织工程研究杂志出版内容重点：干细胞;骨髓干细胞;造血干细胞;脂肪干细胞;肿瘤干细胞;胚胎干细胞;脐带脐血干细胞;干细胞诱导;干细胞分化;组织工程全文链接：     

人脐血单个核细胞静脉移植联合培哚普利对急性心肌梗死炎症反应的影响

背景：近期报道骨髓间充质干细胞心肌内直接移植联合培哚普利治疗急性心肌梗死大鼠,可改善心肌组织内环境,并增强急性心肌梗死疗效。 目的：观察人脐血单个核细胞静脉移植联合血管紧张素转化酶抑制剂培哚普利对家兔急性心肌梗死心肌组织炎症反应与促炎因子白细胞介素6表达及心功能影响,并探讨联合治疗对急性心肌梗死可能的保护机制。 方法：人脐血单个核细胞取自健康足月分娩产妇脐血。60只健康家兔制备急性心肌梗死模型,建模成功后随机数字表法均分对照组、培哚普利组、单纯移植组和联合治疗组。每组随机选5只家兔分别于移植后1,2,4周超声心动图检测家兔心功能指标左室射血分数及左室短轴缩短率;苏木精-伊红染色光镜观察心肌病理变化和白细胞计数;免疫组化检测心肌组织白细胞介素6蛋白表达量;荧光显微镜观测绿色荧光蛋白阳性细胞。 结果与结论：①与对照组比较,培哚普利组、单纯移植组、联合治疗组治疗后1,2,4周心功能指标左室短轴缩短率及左室射血分数改善(P < 0.05),单纯移植组高于培哚普利组(P < 0.05),联合治疗组改善最显著(P < 0.05)。②与对照组比较,培哚普利组、单纯移植组、联合治疗组治疗后1,2,4周心肌组织白细胞计数及白细胞介素6的表达均显著减低(P < 0.05),且单纯移植组低于培哚普利组(P < 0.05),联合治疗组最低(P < 0.05)。③联合治疗组、单纯移植组治疗后1,2,4周均可见绿色荧光蛋白阳性细胞散在分布于梗死周边区域,且联合治疗组细胞计数多于单纯移植组(P < 0.05)。说明培哚普利联合人脐血单个核细胞静脉移植治疗急性心肌梗死实验动物,能提高移植细胞在心肌组织内存活率,并进一步改善心功能。其机制可能与联合治疗抑制心肌局部炎症反应及促炎因子白细胞介素6水平表达作用增强有关。     

静脉移植人脐血细胞促进家兔急性心肌梗死血管再生

目的 探讨静脉移植人脐血细胞(HUCBCs)对家兔急性心肌梗死(AMI)血管再生的影响。方法 家兔随机分为,(1)假手术组:冠状动脉左前降支穿线不结扎;(2)模型组及(3)细胞移植组:结扎左前降支建立急性心肌梗死模型,各组均 15只。造模后24h,细胞移植组经耳缘静脉注入含2×107个人脐血单个核细胞的细胞悬液0.5mL;假手术组、模型组同法注入等量生理盐水。移植后1、2和4周超声检测心功能;免疫组化检测心肌BrdU阳性细胞及VIII因子染色检测血管新生;RT-PCR检测心肌组织VEGFmRNA表达。结果 移植组心功能明显改善,左室短轴缩短率及左室射血分数均明显升高(P＜0.05);移植组心梗区毛细血管密度显著增加(P＜0.01),BrdU阳性细胞分布于其梗死周边区域;移植后心肌组织VEGFmRNA表达显著上调(P＜0.01)。结论 促进血管再生是脐血细胞移植治疗急性心肌梗死的主要机制之一。     

人脐血单个核细胞中CD133+细胞移植治疗心力衰竭的评价

BACKGROUND:Cell purification can eliminate the biological variability of cells, providing new insight into cell regeneration therapy. OBJECTIVE:To study the Influence of CD133⁺ cells on human umbilical cord blood mononuclear cell transplantation for treatment of heart failure. METHODS:Human cord blood mononuclear cells were isolated using lymphocyte separation medium method, and CD133⁺ and CD133^- cells were sorted using immunomagnetic beads at a cell density of 1×10⁸/L. Forty Sprague-Dawley rats were randomized into five groups: sham group, model group, CD133⁺ cell group, CD133^- cell group and mononuclear cell group. Animal models of heart failure were made using intraperitoneal injection of isoproterenol in all the groups except for the sham group. Rats in the CD133⁺ cell group and CD133^- cell group were given 1 mL CD133⁺ cells plus 1 mL PBS and 1 mL CD133^- cells plus 1 mL PBS via the tail vein, respectively. Rats in the mononuclear cell group were given 1 mL CD133⁺ cells plus 1 mL CD133^- cells via the tail vein, and those in the sham and model groups given 2 mL PBS via the tail vein. After 4 weeks, cardiac pathology, degree of myocardial fibrosis and colonization of CD133⁺ cells in myocardial tissues were observed. RESULTS AND CONCLUSION:Hematoxylin-eosin staining showed that myocardial tissues arranged disorderly in the model group, but regularly in the sham group; myocardial disorders were mildest in the CD133⁺ cell group, successively followed by the mononuclear cell group, and severest in the CD133^- cell group and model group. Masson staining showed that in the model group, collagen fibers were proliferated, arranged irregularly and even broken, while in the sham group, the collagen fibers were less in number and arranged in order. Additionally, there was less reduction in collagen fibers and milder myocardial disorders in the CD133⁺ cell group compared with the other groups. Area of collagen fibers was increased significantly in all the groups except for the sham group (P < 0.05), but this increment was the minimal in the CD133⁺ cell group. Findings from immunohistochemistry and immunofluorescence staining showed that there were no CD133⁺ cells in the myocardial tissues of rats. Therefore, our data indicate that compared with the mononuclear cell transplantation, CD133⁺ cell transplantation exerts superiorities in relieving myocardial damage and reducing myocardial fibrosis. However, CD133⁺ cells are not colonized in the myocardial tissue after transplantation.     

两步法分离人脐血单个核细胞的最佳条件

背景：如何获得较为纯化、高活性的干细胞,目前未见深入研究报告,也未见一个标准化操作流程方案。 目的：探讨两步法分离人脐血单个核细胞最佳分离条件。 方法：观察羟乙基淀粉在20,30,40,50,60,70 min不同时间沉淀脐血中红细胞的效果;使用人淋巴细胞分离液,分别在800,700,600,500,400 g/min,离心30,25,20 min的条件下分离人脐血单个核细胞。 结果与结论：6%羟乙基淀粉沉淀脐血60 min效果最好;使用密度为(1.077 0±0.000 1) g/mL人淋巴细胞分离液,在4 ℃条件下以700 g/min离心力,离心30 min,洗涤3次,这样获得的人脐血单个核细胞效果最好,所得细胞沉淀中混杂细胞如红细胞及其他细胞碎片较少,人脐血单个核细胞的细胞得率及活力比较高。提示应用羟乙基淀粉沉淀和人淋巴细胞分离液分离两步法,在最佳时间条件下可提高脐血干细胞的回收率。     

用健康人脐带血单个核细胞分离麻疹野病毒

麻疹是由麻疹病毒感染引起的一种急性传染病。WHO提出麻疹可能是继人类消灭天花和脊髓灰质炎之后的第三个候选消灭的传染病，为此必须建立敏感、快速的病原学诊断监测方法。病毒分离是麻疹病原学监测的一种重要手段，不能完全由血清学检查方法所代替。本文尝试用健康产婴脐血单个核细胞（CBMCs）自出疹病人外周血单个核细胞（PBMCs）中分离麻疹野病毒，取得良好结果。现报道如下：     

脐血单个核细胞移植治疗冠状动脉性心脏病合并心力衰竭的安全性

背景：多项实验和临床研究表明,干细胞移植可能取代坏死心肌、建立新生血管、改善心脏功能,明显改善心血管疾病患者临床症状和预后。 目的：观察新生儿脐血单个核细胞移植治疗冠状动脉性心脏病合并心力衰竭患者的安全性。 方法：共入选冠状动脉性心脏病合并心力衰竭患者(急性心肌梗死合并心力衰竭6例,陈旧心肌梗死合并心力衰竭6例)12例,入院后在常规药物与介入治疗基础上,经皮经腔导管建立冠状动脉通道,利用微导管移植分离的新生儿脐血单个核细胞悬液。细胞移植后1周进行常规抽血检查,与移植前对比血常规、肝肾功能、免疫指标的变化。 结果与结论：脐血单个核细胞移植后有1例发热,不良反应发生率为8.3%,无微栓塞发生,随访1周无移植物抗宿主病发生。与细胞移植治疗前比较,治疗后1周血常规、肝功能、肾功能、C-反应蛋白、IgA、IgG等指标差异无显著性意义。说明新生儿脐血单个核细胞移植治疗冠状动脉性心脏病死合并心功能衰竭在短期是安全的。中国组织工程研究杂志出版内容重点：干细胞;骨髓干细胞;造血干细胞;脂肪干细胞;肿瘤干细胞;胚胎干细胞;脐带脐血干细胞;干细胞诱导;干细胞分化;组织工程全文链接：     

人脐血单个核细胞移植前后自闭症患儿脑脊液中细胞生长因子的表达

背景：研究发现脐血单个核细胞治疗自闭症具有一定的效果。 目的：观察人脐血单个核细胞移植治疗自闭症患儿脑脊液中神经生长因子、血管内皮细胞生长因子、碱性成纤维细胞生长因子水平的变化。 方法：经腰穿蛛网膜下腔途径,以2×106/kg异体人脐血单个核细胞移植治疗30例儿童自闭症患者,1次/周,共治疗3次。 结果与结论：第2次移植1周后患儿脑脊液中神经生长因子较移植前、第1次移植1周后水平增高(P < 0.05),血管内皮细胞生长因子及碱性成纤维细胞生长因子水平均较移植前、第1次移植1周后水平增高,但差异无显著性意义 (P > 0.05)。说明人脐血单个核细胞移植治疗自闭症患儿脑脊液中神经生长因子水平明显增高,血管内皮细胞生长因子及碱性成纤维细胞生长因子变化不明显。     

脐血单个核细胞移植治疗失代偿期肝硬化

背景：原位肝移植是目前治疗终末期肝病的最有效手段,但是供肝来源匮乏、免疫排斥、无法有效控制反复感染等问题限制了其应用。干细胞移植技术的应用为该病种的治疗提供了新的思路和研究方法,许多研究证实可以通过各种不同的方法在体外成功诱导脐血来源的间充质干细胞向肝细胞转化。 目的：探讨人脐血单个核细胞移植治疗失代偿期肝硬化的临床疗效及可行性。 方法：异体人脐血单个核细胞移植治疗23例肝硬化失代偿期患者,检测移植后2,4,8,24周的血清丙氨酸氨基转移酶、白蛋白、胆碱酯酶、总胆红素和凝血酶原时间,并观察患者临床症状体征改善情况以及不良反应。 结果与结论：人脐血单个核细胞移植后2周,肝功能各项指标较治疗前无明显改善(P > 0.05);移植后4周,谷丙转氨酶有显著改善(P < 0.05)、其余指标无明显改善;移植后12周肝功能各项指标均有改善(P < 0.05),且肝脏硬度有所改善(P < 0.05);移植后24周各项指标有显著性改善(P < 0.01)。移植后4周时患者临床症状有明显改善,20例乏力好转(87%)、21例食欲改善(91%)、19例腹水减轻(83%);所有患者移植期间及治疗后随访24周无严重不良反应。结果显示异体人脐血单个核细胞移植治疗肝硬化失代偿期患者临床疗效肯定,安全性好,可作为中晚期肝硬化患者的临床治疗手段。     

外周血间充质干细胞移植心肌梗死兔新生血管及心功能的变化

背景：药物治疗和支架置入治疗尚不能修复心肌梗死后已坏死的心肌。 目的：观察外周血间充质干细胞移植治疗对心肌梗死兔新生血管及心功能的影响。 方法：随机抽签法将36只大白兔分为假手术组,间充质干细胞移植组和对照组,结扎兔冠状动脉左室支建立心肌梗死模型。 结果与结论：移植后4周,流式细胞仪分析显示绝大部分间充质干细胞表达CD44,极少量细胞表达CD34和CD45。间充质干细胞移植组梗死心肌组织有移植的间充质干细胞存活,超声心动仪示间充质干细胞移植组左心室射血分数及短轴缩短率明显高于对照组(P < 0.01);左心室收缩末内径和舒张末内径明显小于对照组(P < 0.01)。间充质干细胞移植组心肌纤维化程度、心肌梗死面积均明显小于对照组(P < 0.01)。免疫组织化学染色显示间充质干细胞移植组新生毛细血管密度明显高于对照组(P < 0.01)。提示外周血间充质干细胞移植增加了梗死心肌新生血管密度,改善心脏的功能。     

Human cord blood mononuclear cells decrease cytokines and inflammatory cells in acute myocardial infarction

We investigated whether human umbilical cord blood mononuclear cells (HUCBC), which contain hematopoietic and mesenchymal progenitor cells, can limit myocardial cytokine expression and inflammatory cell infiltration in acute myocardial infarction. We permanently ligated the left coronary artery of rats and injected into the myocardium either Isolyte or 4 x 10(6) HUCBC in Isolyte and measured myocardial cytokines with antibody arrays at 2, 6, 12, 24, and 72 hours after infarction. We then measured with flow cytometry myocardial macrophages, neutrophils and lymphocytes at 12, 24, and 72 hours after infarctions in rats treated with either intramyocardial Isolyte or 4 x 10(6) HUCBC. In the Isolyte-treated hearts, between 2 and 12 hours after myocardial infarction, tumor necrosis factor-alpha increased from 6.7 +/- 0.9% to 52.3 +/- 4.7%, monocyte chemoattract protein increased from 9.5 +/- 1.2% to 39.8 +/- 2.1%, fractalkine increased from 11 +/- 1.5% to 28.1 +/- 1.3%, ciliary neurotrophic factor increased from 12.1 +/- 0.02% to 25.9 +/- 1.1%, macrophage inflammatory protein increased from 10.3 +/- 1.5% to 23.9.0 +/- 1.4%, interferon-gamma increased from 8.7 +/- 0.4% to 26.0 +/- 1.6%, interleukin-1beta increased from 6.1 +/- 0.04% to 19.0 +/- 1.2%, and IL-4 increased from 5.9 +/- 0.03% to 15 +/- 1.5% (all p < 0.001 compared with controls). The concentrations of fractalkine remained significantly increased at 72 hours after acute infarction. In contrast, the myocardial concentrations of these cytokines did not significantly change in HUCBC treated hearts at 2, 6, 12, 24, or 72 hours after infarction. The percentage of neutrophils increased from 0.04 +/- 0.2%/50,000 heart cells in the controls to 5.3 +/- 1.2%/50,000 heart cells 12 hours after infarction in Isolyte-treated hearts but averaged only 1.3 +/- 0.7%/50,000 heart cells in HUCBC treated hearts (p < 0.02). Thereafter, the percentages of neutrophils rapidly decreased at 24 and at 72 hours after infarction and averaged 0.6 +/- 0.2%/50,000 heart cells at 72 hours after infarction in Isolyte-treated hearts in contrast to 0.2 +/- 0.1%/50,000 cells in HUCBC hearts (p < 0.05). Moreover, the percentages of neutrophils at 24 and 72 hours in HUCBC hearts were not significantly different from controls. At 24 hours post infarction, the percentage of CD3 and CD4 lymphocytes were 10.7 +/- 1.4% and 6.3 +/- 1.1%/50,000 cells in Isolyte hearts in comparison with only 4.9 +/- 0.8% and 2.9 +/- 0.5% in HUCBC hearts (p < 0.005 for Isolyte versus HUCBC). The percentage of CD11b macrophages was 2.8 +/- 0.3% in Isolyte hearts and 1.9 +/- 0.2% in HUCBC treated hearts (p < 0.05). At 72 hours after infarction, the percentage of CD3 and CD4 lymphocytes averaged 8.0 +/- 1.1% and 5.1 +/- 0.8%/50,000 heart cells in Isolyte hearts in comparison with only 4.1 +/- 0.5% and 2.3 +/- 0.4%/50,000 heart cells in the HUCBC treated infarctions (p < 0.005). Left ventricular infarct sizes in Isolyte-treated hearts at 72 hours post infarction averaged 15.7 +/- 1.4% of the left ventricular muscle area in contrast to HUCBC treated infarctions that averaged 6.9 +/- 1.4% of the left ventricular muscle area (p < 0.02). Moreover in rats followed for 2 months post infarction, the LV ejection fractions decreased to 65.4 +/- 1.9% and 69.1 +/- 1.9% at 1 and 2 months after infarction in Isolyte-treated hearts and were significantly different from HUCBC treated hearts that averaged 72.1 +/- 1.3% and 75.7 +/- 1.4% (both p < 0.02). The present experiments suggest that an important mechanism whereby HUCBC limit infarct size and improve left ventricular ejection fraction is by significantly limiting inflammatory cytokines and inflammatory cells in infarcted myocardium.     

卡维地洛缓解兔心肌梗死后心室重构

冠心病患者发生心力衰竭最常见的始动因素是心肌梗死(myocardial infarction,MI),由梗死心肌触发的一系列体液及细胞外基质的改变等因素将导致心脏结构异常,即心室重构.研究表明,MI后心室重构是发生心室功能障碍和心力衰竭的重要原因.因此,抑制心室重构已成为心血管领域备受关注的课题.本实验旨在研究卡维地洛对心室重构的影响.     

Pathomorphological characteristics of cardiac remodeling after myocardial infarction

Dilatational, hypertrophic, aneurysmal, and endocardial variants of remodeling were revealed in the postinfarction heart. The most prevalent dilatational remodeling is characterized by uniform or nonuniform elongation of ventricular cavities and increase in ventricular volume. Characteristic features of the hypertrophic type are hypertrophied interventricular septa and left ventricular wall and reduced or unchanged left ventricular volume. Pronounced changes in the configuration of the left ventricle due to the formation of single or multiple aneurysms were typical of aneurysmal remodeling. Endocardial remodeling was characterized by cicatricial changes and smoothed relief of the parietal endocardium. These variants and forms of remodeling determine disturbances in intracardial hemodynamic and thanatogenesis in the postinfarction period.     

Effects of renal impairment on cardiac remodeling and clinical outcomes after myocardial infarction

How renal function influences post-acute myocardial infarction (AMI) cardiac remodeling and outcomes remains unclear. This study evaluated the impact of levels of renal impairment on drug therapy, echocardiographic parameters, and outcomes in patients with AMI undergoing percutaneous coronary intervention (PCI). A total of 611 patients diagnosed with AMI underwent successful PCI, and two echocardiographic examinations were performed within 1 year after AMI. Patients were categorized according to Group 1: severely impaired estimated glomerular filtration rate (eGFR)<30, Group 2: mildly impaired 30≤eGFR<60, Group 3: potentially at risk 60≤eGFR<90 and normal eGFR≥90 ml/min/1.73 m2. During the 5-year follow-up period, the primary endpoints were cardiovascular mortality and outcomes. Patients with worse renal function (eGFR<30) were older and had a higher prevalence of hypertension and diabetes, but relatively few were smokers or had hyperlipidemia. Despite more patients with lesions of the left anterior descending artery, those with worse renal function received suboptimal guideline-directed medical therapy (GDMT). Notably, patients with worse renal function presented with worse left ventricular function at baseline and subsequent follow-up. Kaplan-Meier analysis revealed increased cardiovascular death, development of heart failure, recurrent AMI and revascularization in patients with worse renal function. Notably, as focusing on patients with ST elevation MI, the similar findings were observed. In multivariable Cox regression, impaired renal function showed the most significant hazard ratio in cardiovascular death. Collectively, in AMI patients receiving PCI, outcome differences are renal function dependent. We found that patients with worse renal function received less GDMT and presented with worse cardiovascular outcomes. These patients require more attention.     

岩藻多糖抑制小鼠心肌梗死后的心脏重构

目的 观察裙带菜提取物岩藻多糖对小鼠心肌梗死后心脏重构的影响.方法 将小鼠随机分为假手术组、心肌梗死模型组(采用冠状动脉左前降支结扎建立该模型)、低浓度或高浓度岩藻多糖处理组(心肌梗死术后每日灌胃给予200或500 mg/kg岩藻多糖处理).每日观察小鼠死亡情况,3周后采用超声心动图检测心功能,病理染色检测心肌梗死面积和,用RT-PCR检测心肌SOD、诱导型一氧化氮合酶(iNOS)以及炎性因子TNFα、IL-1β和TGFβmRNA表达,Western blot检测eNOS信号通路相关蛋白.结果 岩藻多糖能明显改善心肌梗死小鼠的心功能(P＜0.05)、减少梗死面积(P＜0.05),提高生存率(P＜0.05).与对照组相比,心肌iNOS和炎性因子TNFα、IL-1β及TGFβ mRNA表达明显下降(P＜0.05),SOD mRNA的表达明显增高(P＜0.05);岩藻多糖能激活eNOS信号通路.结论 岩藻多糖能减轻小鼠心肌梗死,其作用机制可能与其抗炎、抗氧化及激活eNOS信号通路有关.     

瑞舒伐他汀联合脐血间充质干细胞移植改善急性心肌梗死后心功能

BACKGROUND:In recent years, it has been a hot topic that stem cell transplantation is used to improve cardiac insufficiency after acute myocardial infarction by inducing regeneration of cardiomyocytes in the infarction regions. OBJECTIVE:To observe the effect of rosuvastatin combined with umbilical cord blood mesenchymal stem cells transplantation on rat cardiac function after acute myocardial infarction. METHODS:Forty-five Sprague-Dawley rats were enrolled to prepare myocardial infarction models by ligaturing the left anterior descending coronary artery. Then they were equivalently divided into model group, transplantation group and combination group. At 7 days after modeling, rats in the combination group were given injection of 300 μL umbilical cord blood mesenchymal stem cells (15.0×10⁸) via the tail vein and by gavage once a day for 28 days with 1 mg/kg rosuvastatin; rats in the transplantation group and model group were injected with 300 μL umbilical cord blood mesenchymal stem cell suspension through the tail veins or the same amount of LG-DMEM medium, respectively, followed by intragastrical administration of the same amount normal saline. At 5 weeks after modeling, indexes of cardiac function, level of plasma Lp-PLA2 and heat shock protein 70 in the infarction regions were detected by color Doppler ultrasound, enzyme-linked immunosorbent assay and western blot assay, respectively. In addition, pathological changes of myocardial tissues were observed using hematoxylin-eosin staining. RESULTS AND CONCLUSION:Left ventricular ejection fraction and left ventricular end-systolic pressure were significantly higher in the combination group than in the transplantation group as well as higher in the transplantation group than the model group (P < 0.05); compared with the transplantation group, left ventricular end-diastolic pressure was significantly decreased in the combination group, but significantly increased in the model group (P < 0.05); the number of cardiomyocytes in the infarction regions was significantly higher in the combination group than the other groups. Additionally, expression of heat shock protein 70 in the infarction regions was significantly increased in the combination group (P < 0.05). To conclude, rosuvastatin combined with umbilical cord blood mesenchymal stem cell transplantation can significantly improve rat cardiac function after myocardial infarction.     

大鼠急性心肌梗死心室重塑中细胞因子与胶原的变化

目的:探讨大鼠急性心肌梗死（MI）后心室重塑过程细胞因子与胶原分子的关系。 方法:制备雄性Wistar大鼠心肌梗死和假手术对照模型，于手术后3 d、1 w、4 w分别观察不同时点梗死区和非梗死区的Ⅰ、Ⅲ型胶原及炎症因子的mRNA变化。 结果:心肌梗死后第3 d胶原（Ⅰ、Ⅲ型胶原）和细胞因子（TGF-β1、TNF-α）皆上升，梗死区Ⅰ、Ⅲ型胶原在第4周仍然比非梗死区为高，TGF-β1、TNF-α在第1周达到高峰后逐渐下降但仍高于同期假手术组（P＜0.01），相关性分析提示梗死区和非梗死区TGF-β1、TNF-α均与Ⅰ、Ⅲ型胶原存在相关（P<0.01）。 结论:炎症因子参与心室重塑的病理生理过程，干预细胞因子可能作为早期防治心室重塑的手段。